{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:00:37Z","timestamp":1775059237549,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.critrevonc.2012.03.007","type":"journal-article","created":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T16:30:55Z","timestamp":1335198655000},"page":"340-349","source":"Crossref","is-referenced-by-count":28,"title":["Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis"],"prefix":"10.1016","volume":"84","author":[{"given":"Gaetan","family":"Des Guetz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Uzzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Valeyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Sebbane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Morere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2012.03.007_bib0005","unstructured":"Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review. http:\/\/seer.cancer.gov\/csr\/1975_2005\/; 1975\u20132005."},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0010","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0015","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1200\/JCO.2004.05.031","article-title":"Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-medicare","volume":"22","author":"Ramsey","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0020","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.2001.19.4.1147","article-title":"Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base","volume":"19","author":"Yancik","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0025","first-page":"49","article-title":"Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC)","volume":"81","author":"Klastersky","year":"2012","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0030","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"American society of clinical oncology clinical practice guideline update on chemotherapy for Stage IV non-small-cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0035","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/CAD.0b013e32833ab7a0","article-title":"Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial","volume":"21","author":"Zwitter","year":"2010","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0040","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.lungcan.2007.12.009","article-title":"A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly","volume":"61","author":"Chen","year":"2008","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0045","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2000.18.13.2529","article-title":"Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer","volume":"18","author":"Frasci","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0050","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1200\/JCO.2005.01.2781","article-title":"Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish lung cancer study group","volume":"23","author":"Sederholm","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0055","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2005.07.172","article-title":"Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia Group B (study 9730)","volume":"23","author":"Lilenbaum","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0060","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/cncr.23019","article-title":"Weekly docetaxel versus docetaxel\/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer","volume":"110","author":"Hainsworth","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.bjc.6602011","article-title":"Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients","volume":"91","author":"Comella","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0070","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/95.5.362","article-title":"Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter italian lung cancer in the elderly study (MILES) Phase III randomized trial","volume":"95","author":"Gridelli","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0075","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(11)60780-0","article-title":"Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial","volume":"378","author":"Quoix","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0080","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2008.19.1650","article-title":"Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer","volume":"27","author":"Smit","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0085","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1186\/1471-2407-10-633","article-title":"A randomized phase III study of the docetaxel\/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced\/metastatic non-small cell lung cancer","volume":"10","author":"Pallis","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0090","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2009.06.026","article-title":"A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with non-small cell lung cancer","volume":"68","author":"Kim","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0169-5002(03)00356-8","article-title":"Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer","volume":"42","author":"Maestu","year":"2003","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0100","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/cncr.21495","article-title":"Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326)","volume":"104","author":"Belani","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0105","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.06.1044","article-title":"Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non small-cell lung cancer: results of the west Japan thoracic oncology group trial (WJTOG 9904)","volume":"24","author":"Kudoh","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0110","series-title":"Docetaxel plus carboplatin versus docetaxel for the patients with old age or poor performance in advanced non-small cell lung cancer: randomized phase III study","author":"Kang","year":"2009"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0115","series-title":"The 2nd European lung cancer conference","first-page":"S87","article-title":"Docetaxel (D) versus docetaxel\/Gemcitabine (D&G) in the treatment of older patients with advanced non small cell lung cancer patients (NSCLC): An Alpe Adria thoracic Oncology Multidisciplinary group randomized phase II trial (ATOM 017)","author":"Rijavec","year":"2010"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0120","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1200\/jco.2007.25.18_suppl.7629","article-title":"Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207","volume":"25","author":"Tsukada","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0125","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1200\/JCO.2004.11.004","article-title":"Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial","volume":"22","author":"Georgoulias","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0130","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1200\/jco.2010.28.15_suppl.7605","article-title":"Docetaxel (D) plus gemcitabine (G) compared with G in elderly patients with advanced non-small cell lung cancer (NSCLC): preliminary results of a randomized phase III Hellenic Oncology Research Group trial","volume":"28","author":"Karampeazis","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0135","series-title":"ASCO Meeting Abstracts, vol. 29","first-page":"7509","article-title":"Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): an intergroup trial of JCOG0803\/WJOG4307L","author":"Abe","year":"2011"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2007.06.008","article-title":"An open multicenter phase II trial of docetaxel,gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura\/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study","volume":"64","author":"LeCaer","year":"2007","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0145","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer","volume":"25","author":"Extermann","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0150","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/cncr.24207","article-title":"Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer","volume":"115","author":"Russo","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2012.03.007_bib0155","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.critrevonc.2011.05.003","article-title":"Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer","volume":"82","author":"Wozniak","year":"2012","journal-title":"Critical Reviews in Oncology\/Hematology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842812000868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842812000868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T10:46:20Z","timestamp":1594032380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842812000868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1040842812000868"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2012.03.007","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}